nach oben

Drugs & Aging

Erschienen in:

01.07.2011 | Therapy In Practice

Elderly Patients with Community-Acquired Pneumonia

Optimal Treatment Strategies

verfasst von: Dr Ulrich Thiem, Hans-Jürgen Heppner, Ludger Pientka

Erschienen in: Drugs & Aging | Ausgabe 7/2011

Einloggen, um Zugang zu erhalten

Abstract

Community-acquired pneumonia (CAP) is a common infectious disease that still causes substantial morbidity and mortality. Elderly people are frequently affected, and several issues related to care of this condition in the elderly have to be considered. This article reviews current recommendations of guidelines with a special focus on aspects of the care of elderly patients with CAP.

The most common pathogen in CAP is still Streptococcus pneumoniae, followed by other pathogens such as Haemophilus influenzae, Mycoplasma pneumoniae, Chlamydophila pneumoniae and Legionella species. Antimicrobial resistance is an increasing problem, especially with regard to macrolide-resistant S. pneumoniae and fluoroquinolone-resistant strains. With regard to β-lactam antibacterials, resistance by H. influenzae and Moraxella catarrhalis is important, as is the emergence of multidrug-resistant Staphylococcus aureus. The main management decisions should be guided by the severity of disease, which can be assessed by validated clinical risk scores such as CURB-65, a tool for measuring the severity of pneumonia based on assessment of confusion, serum urea, respiratory rate and blood pressure in patients aged ≥65 years.

For the treatment of low-risk pneumonia, an aminopenicillin such as amoxicillin with or without a β-lactamase inhibitor is frequently recommended. Monotherapy with macrolides is also possible, although macrolide resistance is of concern. When predisposing factors for special pathogens are present, a β-lactam antibacterial combined with a β-lactamase inhibitor, or the combination of a β-lactam antibacterial, a β-lactamase inhibitor and a macrolide, may be warranted. If possible, patients who have undergone previous antibacterial therapy should receive drug classes not previously used.

For hospitalized patients with non-severe pneumonia, a common recommendation is empirical antibacterial therapy with an aminopenicillin in combination with a β-lactamase inhibitor, or with fluoroquinolone monotherapy. With proven Legionella pneumonia, a combination of β-lactams with a fluoroquinolone or a macrolide is beneficial. In severe pneumonia, ureidopenicillins with β-lactamase inhibitors, broad-spectrum cephalosporins, macrolides and fluoroquinolones are used. A combination of a broad-spectrum β-lactam antibacterial (e.g. cefotaxime or ceftriaxone), piperacillin/tazobactam and a macrolide is mostly recommended. In patients with a predisposition for Pseudomonas aeruginosa, a combination of piperacillin/tazobactam, cefepime, imipenem or meropenem and levofloxacin or ciprofloxacin is frequently used. Treatment duration of more than 7 days is not generally recommended, except for proven infections with P. aeruginosa, for which 15 days of treatment appears to be appropriate. Further care issues in all hospitalized patients are timely administration of antibacterials, oxygen supply in case of hypoxaemia, and fluid management and dose adjustments according to kidney function.

The management of elderly patients with CAP is a challenge. Shifts in antimicrobial resistance and the availability of new antibacterials will change future clinical practice. Studies investigating new methods to detect pathogens, determine the optimal antimicrobial regimen and clarify the duration of treatment may assist in further optimizing the management of elderly patients with CAP.

World Health Organization (WHO). The global burden of disease: 2004 update. Geneva: World Health Organization, 2008

Foy HM, Cooney MK, Allan I, et al. Rates of pneumonia during influenza epidemics in Seattle, 1964 to 1975. JAMA 1979; 241: 253–8PubMedCrossRef

Jokinen C, Heiskanen L, Juvonen H, et al. Incidence of community-acquired pneumonia in the population of four municipalities in eastern Finland. Am J Epidemiol 1993; 137: 977–88PubMed

Woodhead M, Macfarlane J, McCracken J, et al. Prospective study of the aetiology and outcome of pneumonia in the community. Lancet 1987; I: 671–4CrossRef

Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007 Mar 1; 44Suppl. 2: S27–72PubMedCrossRef

Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 2005; 26(6): 1138–80PubMedCrossRef

Lim WS, Baudouin SV, George RC, et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax 2009; 64Suppl. 3: iii1–55PubMedCrossRef

Hoffken G, Lorenz J, Kern W, et al. S3-guideline on ambulant acquired pneumonia and deep airway infections. Pneumologie 2009; 63: e1–68PubMedCrossRef

ACPG Group. The diagnosis and management of community acquired pneumonia: adult. Edmonton: Alberta Medical Association, 2008

10.

Schouten JA, Prins JM, Bonten MJ, et al. Revised SWAB guidelines for antimicrobial therapy of community-acquired pneumonia. Neth J Med 2005; 63(8): 323–35PubMed

11.

Working Group of the South African Thoracic Society. Management of community-acquired pneumonia in adults. SAMJ 2007; 97: 1295–306

12.

Menendez R, Torres A, Aspa J, et al. Community acquired pneumonia: new guidelines of the Spanish Society of Chest Diseases and Thoracic Surgery (SEPAR). Arch Bronconeumol 2010; 46(10): 543–58PubMedCrossRef

13.

Chen JH, Chang SS, Liu JJ, et al. Comparison of clinical characteristics and performance of pneumonia severity score and CURB-65 among younger adults, elderly and very old subjects. Thorax 2010; 65(11): 971–7PubMedCrossRef

14.

Sligl WI, Eurich DT, Marrie TJ, et al. Age still matters: prognosticating short- and long-term mortality for critically ill patients with pneumonia. Crit Care Med 2010; 38(11): 2126–32PubMedCrossRef

15.

Sligl WI, Majumdar SR. How important is age in defining the prognosis of patients with community-acquired pneumonia? Curr Opin Infect Dis 2011; 24(2): 142–7PubMedCrossRef

16.

Fine MJ, Orloff JJ, Arisumi D, et al. Prognosis of patients hospitalized with community-acquired pneumonia. Am J Med 1990; 88(5N): 1N–8NPubMed

17.

Fernandez-Sabe N, Carratala J, Roson B, et al. Community-acquired pneumonia in very elderly patients: causative organisms, clinical characteristics, and outcomes. Medicine (Baltimore) 2003; 82(3): 159–69

18.

Marrie TJ. Pneumonia in the elderly. Curr Opin Pulm Med 1996; 2(3): 192–7PubMedCrossRef

19.

Metlay JP, Schulz R, Li YH, et al. Influence of age on symptoms at presentation in patients with community-acquired pneumonia. Arch Intern Med 1997; 157(13): 1453–9PubMedCrossRef

20.

Loeb M. Pneumonia in the elderly. Curr Opin Infect Dis 2004; 17(2): 127–30PubMedCrossRef

21.

Metlay JP, Kapoor WN, Fine MJ. Does this patient have community-acquired pneumonia? Diagnosing pneumonia by history and physical examination. JAMA 1997; 278(17): 1440–5PubMedCrossRef

22.

Espana PP, Capelastegui A, Quintana JM, et al. Validation and comparison of SCAP as a predictive score for identifying low-risk patients in community-acquired pneumonia. J Infect 2010; 60(2): 106–13PubMedCrossRef

23.

Yandiola PP, Capelastegui A, Quintana J, et al. Prospective comparison of severity scores for predicting clinically relevant outcomes for patients hospitalized with community-acquired pneumonia. Chest 2009; 135(6): 1572–9PubMedCrossRef

24.

Yanagihara K, Izumikawa K, Higa F, et al. Efficacy of azithromycin in the treatment of community-acquired pneumonia, including patients with macrolide-resistant Streptococcus pneumoniae infection. Intern Med 2009; 48(7): 527–35PubMedCrossRef

25.

Torres A, Garau J, Arvis P, et al. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study — a randomized clinical trial. Clin Infect Dis 2008; 46(10): 1499–509PubMedCrossRef

26.

IDSA. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171(4): 388–416CrossRef

27.

Zilberberg MD, Shorr AF. Healthcare-associated pneumonia: the state of evidence to date. Curr Opin Pulm Med 2011; 17(3): 142–7PubMedCrossRef

28.

Rello J, Lujan M, Gallego M, et al. Why mortality is increased in health-care-associated pneumonia: lessons from pneumococcal bacteremic pneumonia. Chest 2010 May; 137(5): 1138–44PubMedCrossRef

29.

Venditti M, Falcone M, Corrao S, et al. Outcomes of patients hospitalized with community-acquired, health care-associated, and hospital-acquired pneumonia. Ann Intern Med 2009; 150(1): 19–26PubMed

30.

Mylotte JM. Nursing home-acquired pneumonia: update on treatment options. Drugs Aging 2006; 23(5): 377–90PubMedCrossRef

31.

Mylotte JM. Nursing home-associated pneumonia. Clin Geriatr Med 2007; 23(3): 553–65, vi-viiPubMedCrossRef

32.

Arancibia F, Bauer TT, Ewig S, et al. Community-acquired pneumonia due to gram-negative bacteria and Pseudomonas aeruginosa: incidence, risk, and prognosis. Arch Intern Med 2002; 162(16): 1849–58PubMedCrossRef

33.

Sopena N, Sabria M, Pedro-Botet ML, et al. Prospective study of community-acquired pneumonia of bacterial etiology in adults. Eur J Clin Microbiol Infect Dis 1999; 18(12): 852–8PubMedCrossRef

34.

Marrie TJ. Bacteraemic pneumococcal pneumonia: a continuously evolving disease. J Infect 1992; 24(3): 247–55PubMedCrossRef

35.

Carbon C. Optimal treatment strategies for community-acquired pneumonia: high-risk patients (geriatric and with comorbidity). Chemotherapy 2001; 47Suppl. 4: 19–25PubMedCrossRef

36.

Paganin F, Lilienthal F, Bourdin A, et al. Severe community-acquired pneumonia: assessment of microbial aetiology as mortality factor. Eur Respir J 2004; 24(5): 779–85PubMedCrossRef

37.

Vanderkooi OG, Low DE, Green K, et al. Predicting antimicrobial resistance in invasive pneumococcal infections. Clin Infect Dis 2005; 40(9): 1288–97PubMedCrossRef

38.

File TM. Community-acquired pneumonia. Lancet 2003; 362(9400): 1991–2001PubMedCrossRef

39.

Andrews J, Nadjm B, Gant V, et al. Community-acquired pneumonia. Curr Opin Pulm Med 2003; 9(3): 175–80PubMedCrossRef

40.

Niederman MS, Ahmed QA. Community-acquired pneumonia in elderly patients. Clin Geriatr Med 2003; 19(1): 101–20PubMedCrossRef

41.

Kothe H, Bauer T, Marre R, et al. Outcome of community-acquired pneumonia: influence of age, residence status and antimicrobial treatment. Eur Respir J 2008; 32(1): 139–46PubMedCrossRef

42.

Welte T, Kohnlein T. Global and local epidemiology of community-acquired pneumonia: the experience of the CAPNETZ Network. Semin Respir Crit Care Med 2009; 30(2): 127–35PubMedCrossRef

43.

Chong CP, Street PR. Pneumonia in the elderly: a review of the epidemiology, pathogenesis, microbiology, and clinical features. South Med J 2008; 101(11): 1141–5PubMedCrossRef

44.

Wulff-Burchfield E, Schell WA, Eckhardt AE, et al. Microfluidic platform versus conventional real-time polymerase chain reaction for the detection of Mycoplasma pneumoniae in respiratory specimens. Diagn Microbiol Infect Dis 2010; 67(1): 22–9PubMedCrossRef

45.

Chakravorty S, Aladegbami B, Burday M, et al. Rapid universal identification of bacterial pathogens from clinical cultures by using a novel sloppy molecular beacon melting temperature signature technique. J Clin Microbiol 2010; 48(1): 258–67PubMedCrossRef

46.

Josko D. Molecular virology in the clinical laboratory. Clin Lab Sci 2010; 23(4): 231–6PubMed

47.

Weile J, Knabbe C. Current applications and future trends of molecular diagnostics in clinical bacteriology. Anal Bioanal Chem 2009; 394(3): 731–42PubMedCrossRef

48.

Klugman KP, Madhi SA, Albrich WC. Novel approaches to the identification of Streptococcus pneumoniae as the cause of community-acquired pneumonia. Clin Infect Dis 2008; 47Suppl. 3: S202–6PubMedCrossRef

49.

De Bruyne K, Slabbinck B, Waegeman W, et al. Bacterial species identification from MALDI-TOF mass spectra through data analysis and machine learning. Syst Appl Microbiol 2010; 34(1): 20–9CrossRef

50.

Benagli C, Rossi V, Dolina M, et al. Matrix-assisted laser desorption ionization-time of flight mass spectrometry for the identification of clinically relevant bacteria. PLoS One 2011; 6(1): e16424PubMedCrossRef

51.

Wikler MA. Performance standards for antimicrobial susceptibility testing: eighteenth informational supplement. Wayne (PA): Clinical and Laboratory Standards Institute, 2008

52.

Cooke B, Smith A, Diggle M, et al. Antibiotic resistance in invasive Streptococcus pneumoniae isolates identified in Scotland between 1999 and 2007. J Med Microbiol 2010; 59(10): 1212–8PubMedCrossRef

53.

Song JH, Oh WS, Kang CI, et al. Epidemiology and clinical outcomes of community-acquired pneumonia in adult patients in Asian countries: a prospective study by the Asian network for surveillance of resistant pathogens. Int J Antimicrob Agents 2008; 31(2): 107–14PubMedCrossRef

54.

Yu VL, Baddour LM. Infection by drug-resistant Streptococcus pneumoniae is not linked to increased mortality. Clin Infect Dis 2004; 39(7): 1086–7PubMedCrossRef

55.

Effects of new penicillin susceptibility breakpoints for Streptococcus pneumoniae: United States, 2006–2007. MMWR Morb Mortal Wkly Rep 2008; 57(50): 1353–5

56.

Yu VL, Chiou CC, Feldman C, et al. An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis 2003; 37(2): 230–7PubMedCrossRef

57.

Percin D, Ay Altintop Y, Sumerkan B. Ten-year surveillance of invasive Streptococcus pneumoniae isolates in central Turkey prior to the introduction of a conjugate vaccine. J Infect Dev Ctries 2010; 4(9): 560–5PubMedCrossRef

58.

Maraki S, Mantadakis E, Samonis G. Serotype distribution and antimicrobial resistance of adult Streptococcus pneumoniae clinical isolates over the period 2001–2008 in Crete, Greece. Chemotherapy 2010; 56(4): 325–32PubMedCrossRef

59.

Imohl M, Reinert RR, van der Linden M. Serotype-specific penicillin resistance of Streptococcus pneumoniae in Germany from 1992 to 2008. Int J Med Microbiol 2010; 300(5): 324–30PubMedCrossRef

60.

Song JH, Chang HH, Suh JY, et al. Macrolide resistance and genotypic characterization of Streptococcus pneumoniae in Asian countries: a study of the Asian Network for Surveillance of Resistant Pathogens (ANSORP). J Antimicrob Chemother 2004; 53(3): 457–63PubMedCrossRef

61.

Doern GV, Richter SS, Miller A, et al. Antimicrobial resistance among Streptococcus pneumoniae in the United States: have we begun to turn the corner on resistance to certain antimicrobial classes? Clin Infect Dis 2005; 41(2): 139–48PubMedCrossRef

62.

Felmingham D, Reinert RR, Hirakata Y, et al. Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and comparative in vitro activity of the ketolide, telithromycin. J Antimicrob Chemother 2002; 50Suppl. S1: 25–37PubMedCrossRef

63.

van der Linden M, Al-Lahham A, Haupts S, et al. Clonal spread of mef-positive macrolide-resistant Streptococcus pneumoniae isolates causing invasive disease in adults in Germany. Antimicrob Agents Chemother 2007; 51(5): 1830–4PubMedCrossRef

64.

Imohl M, Reinert RR, Mutscher C, et al. Macrolide susceptibility and serotype specific macrolide resistance of invasive isolates of Streptococcus pneumoniae in Germany from 1992 to 2008. BMC Microbiol 2010; 10: 299PubMedCrossRef

65.

Miyashita N, Oka M, Kawai Y, et al. Macrolide-resistant Mycoplasma pneumoniae in adults with community-acquired pneumonia. Int J Antimicrob Agents 2010; 36(4): 384–5PubMedCrossRef

66.

Xu X, Cai L, Xiao M, et al. Distribution of serotypes, genotypes, and resistance determinants among macrolide-resistant Streptococcus pneumoniae isolates. Antimicrob Agents Chemother 2010; 54(3): 1152–9PubMedCrossRef

67.

Daneman N, McGeer A, Green K, et al. Macrolide resistance in bacteremic pneumococcal disease: implications for patient management. Clin Infect Dis 2006; 43(4): 432–8PubMedCrossRef

68.

Plouffe J, Schwartz DB, Kolokathis A, et al. Clinical efficacy of intravenous followed by oral azithromycin monotherapy in hospitalized patients with community-acquired pneumonia: the Azithromycin Intravenous Clinical Trials Group. Antimicrob Agents Chemother 2000; 44(7): 1796–802PubMedCrossRef

69.

Vergis EN, Indorf A, File Jr TM, et al. Azithromycin vs cefuroxime plus erythromycin for empirical treatment of community-acquired pneumonia in hospitalized patients: a prospective, randomized, multicenter trial. Arch Intern Med 2000; 160(9): 1294–300PubMedCrossRef

70.

Song JH, Chung DR. Respiratory infections due to drug-resistant bacteria. Infect Dis Clin North Am 2010; 24: 639–53PubMedCrossRef

71.

Pletz MW, van der Linden M, von Baum H, et al. Low prevalence of fluoroquinolone resistant strains and resistance precursor strains in Streptococcus pneumoniae from patients with community-acquired pneumonia despite high fluoroquinolone usage. Int J Med Microbiol 2011; 301(1): 53–7PubMedCrossRef

72.

Centers for Disease Control and Prevention (CDC). Active bacterial core surveillance report, Emerging Infections Program Network, Streptococcus pneumoniae, 2009 [online]. Available from URL: http://www.cdc.gov/abcs/reports-findings/survreports/spneu09.pdf [Accessed 2011 Feb 28]

73.

Cecere LM, Rubenfeld GD, Park DR, et al. Long-term survival after hospitalization for community-acquired and healthcare-associated pneumonia. Respiration 2010; 79(2): 128–36PubMedCrossRef

74.

Jones RN, Jacobs MR, Sader HS. Evolving trends in Streptococcus pneumoniae resistance: implications for therapy of community-acquired bacterial pneumonia. Int J Antimicrob Agents 2010; 36(3): 197–204PubMedCrossRef

75.

Reinert RR, Reinert S, van der Linden M, et al. Antimicrobial susceptibility of Streptococcus pneumoniae in eight European countries from 2001 to 2003. Antimicrob Agents Chemother 2005; 49(7): 2903–13PubMedCrossRef

76.

Draghi DC, Jones ME, Sahm DF, et al. Geographically-based evaluation of multidrug resistance trends among Streptococcus pneumoniae in the USA: findings of the FAST surveillance initiative (2003–2004). Int J Antimicrob Agents 2006; 28(6): 525–31PubMedCrossRef

77.

Farrell DJ, Couturier C, Hryniewicz W. Distribution and antibacterial susceptibility of macrolide resistance genotypes in Streptococcus pneumoniae: PROTEKT Year 5 (2003–2004). Int J Antimicrob Agents 2008; 31(3): 245–9PubMedCrossRef

78.

Reinert RR, Rodloff AC, Halle E, et al. Antibacterial resistance of community-acquired respiratory tract pathogens recovered from patients in Germany and activity of the Ketolide Telithromycin: results from the PROTEKT surveillance study (1999–2000). Chemotherapy 2004; 50(3): 143–51PubMedCrossRef

79.

Jacobs MR, Felmingham D, Appelbaum PC, et al. The Alexander Project 1998–2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother 2003; 52(2): 229–46PubMedCrossRef

80.

Johnson AP, Sheppard CL, Harnett SJ, et al. Emergence of a fluoroquinolone-resistant strain of Streptococcus pneumoniae in England. J Antimicrob Chemother 2003; 52(6): 953–60PubMedCrossRef

81.

Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336(4): 243–50PubMedCrossRef

82.

Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003; 58(5): 377–82PubMedCrossRef

83.

Bauer TT, Ewig S, Marre R, et al. CRB-65 predicts death from community-acquired pneumonia. J Intern Med 2006; 260(1): 93–101PubMedCrossRef

84.

Chalmers JD, Singanayagam A, Akram AR, et al. Severity assessment tools for predicting mortality in hospitalised patients with community-acquired pneumonia: systematic review and meta-analysis. Thorax 2010; 65(10): 878–83PubMedCrossRef

85.

Ewig S, de Roux A, Bauer T, et al. Validation of predictive rules and indices of severity for community acquired pneumonia. Thorax 2004; 59(5): 421–7PubMedCrossRef

86.

Ewig S, Ruiz M, Mensa J, et al. Severe community-acquired pneumonia: assessment of severity criteria. Am J Respir Crit Care Med 1998; 158(4): 1102–8PubMed

87.

Gharib AM, Stern EJ. Radiology of pneumonia. Med Clin North Am 2001; 85(6): 1461–91PubMedCrossRef

88.

Franquet T. Imaging of pneumonia: trends and algorithms. Eur Respir J 2001; 18(1): 196–208PubMedCrossRef

89.

Esayag Y, Nikitin I, Bar-Ziv J, et al. Diagnostic value of chest radiographs in bedridden patients suspected of having pneumonia. Am J Med 2010; 123(1): 88.e1–5CrossRef

90.

Bodi M, Rodriguez A, Sole-Violan J, et al. Antibiotic prescription for community-acquired pneumonia in the intensive care unit: impact of adherence to Infectious Diseases Society of America guidelines on survival. Clin Infect Dis 2005; 41(12): 1709–16PubMedCrossRef

91.

Ray GT, Baxter R, DeLorenze GN. Hospital-level rates of fluoroquinolone use and the risk of hospital-acquired infection with ciprofloxacin-nonsusceptible Pseudomonas aeruginosa. Clin Infect Dis 2005; 41(4): 441–9PubMedCrossRef

92.

Nseir S, Di Pompeo C, Soubrier S, et al. First-generation fluoroquinolone use and subsequent emergence of multiple drug-resistant bacteria in the intensive care unit. Crit Care Med 2005; 33(2): 283–9PubMedCrossRef

93.

Leroy O, Santre C, Beuscart C, et al. A five-year study of severe community-acquired pneumonia with emphasis on prognosis in patients admitted to an intensive care unit. Intensive Care Med 1995; 21(1): 24–31PubMedCrossRef

94.

Quagliarello V, Ginter S, Han L, et al. Modifiable risk factors for nursing home-acquired pneumonia. Clin Infect Dis 2005; 40(1): 1–6PubMedCrossRef

95.

Yu VL, Stout JE. Rapid diagnostic testing for community-acquired pneumonia: can innovative technology for clinical microbiology be exploited? Chest 2009; 136(6): 1618–21PubMedCrossRef

96.

Olsen CW, Elverdal P, Jorgensen CS, et al. Comparison of the sensitivity of the Legionella urinary antigen EIA kits from Binax and Biotest with urine from patients with infections caused by less common serogroups and subgroups of Legionella. Eur J Clin Microbiol Infect Dis 2009; 28(7): 817–20PubMedCrossRef

97.

Sorde R, Falco V, Lowak M, et al. Current and potential usefulness of pneumococcal urinary antigen detection in hospitalized patients with community-acquired pneumonia to guide antimicrobial therapy. Arch Intern Med 2011; 171(2): 166–72PubMedCrossRef

98.

Smith MD, Sheppard CL, Hogan A, et al. Diagnosis of Streptococcus pneumoniae infections in adults with bacteremia and community-acquired pneumonia: clinical comparison of pneumococcal PCR and urinary antigen detection. J Clin Microbiol 2009; 47(4): 1046–9PubMedCrossRef

99.

Dong K, Quan DJ. Appropriately assessing renal function for drug dosing. Nephrol Nurs J 2010; 37(3): 304–8PubMed

100.

Murphree DD, Thelen SM. Chronic kidney disease in primary care. J Am Board Fam Med 2010; 23(4): 542–50PubMedCrossRef

101.

Olyaei AJ, Bennett WM. Drug dosing in the elderly patients with chronic kidney disease. Clin Geriatr Med 2009; 25(3): 459–527PubMedCrossRef

102.

Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130(6): 461–70PubMed

103.

Stahlmann R, Lode H. Safety considerations of fluoroquinolones in the elderly: an update. Drugs Aging 2010; 27(3): 193–209PubMedCrossRef

104.

Weber S, Mawdsley E, Kaye D. Antibacterial agents in the elderly. Infect Dis Clin North Am 2009; 23(4): 881–98, viiiPubMedCrossRef

105.

Herring AR, Williamson JC. Principles of antimicrobial use in older adults. Clin Geriatr Med 2007; 23(3): 481–97, vPubMedCrossRef

106.

Faulkner CM, Cox HL, Williamson JC. Unique aspects of antimicrobial use in older adults. Clin Infect Dis 2005; 40(7): 997–1004PubMedCrossRef

107.

Shakeri-Nejad K, Stahlmann R. Drug interactions during therapy with three major groups of antimicrobial agents. Expert Opin Pharmacother 2006; 7(6): 639–51PubMedCrossRef

108.

Gordon JJ, Kauffman CA. Superinfection with Streptococcus pneumoniae during therapy with ciprofloxacin. Am J Med 1990; 89(3): 383–4PubMedCrossRef

109.

File Jr TM, Segreti J, Dunbar L, et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother 1997; 41(9): 1965–72PubMed

110.

Gotfried MH, Dattani D, Riffer E, et al. A controlled, double-blind, multicenter study comparing clarithromycin extended-release tablets and levofloxacin tablets in the treatment of community-acquired pneumonia. Clin Ther 2002; 24(5): 736–51PubMedCrossRef

111.

Hoeffken G, Meyer HP, Winter J, et al. The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia. Respir Med 2001; 95(7): 553–64PubMedCrossRef

112.

Scheld WM. Maintaining fluoroquinolone class efficacy: review of influencing factors. Emerg Infect Dis 2003; 9(1): 1–9PubMedCrossRef

113.

Bohte R, van Furth R, van den Broek PJ. Aetiology of community-acquired pneumonia: a prospective study among adults requiring admission to hospital. Thorax 1995; 50(5): 543–7PubMedCrossRef

114.

Fine MJ, Stone RA, Singer DE, et al. Processes and outcomes of care for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team (PORT) cohort study. Arch Intern Med 1999; 159(9): 970–80PubMedCrossRef

115.

Mundy LM, Auwaerter PG, Oldach D, et al. Community-acquired pneumonia: impact of immune status. Am J Respir Crit Care Med 1995; 152(4): 1309–15PubMed

116.

Lieberman D, Schlaeffer F, Boldur I, et al. Multiple pathogens in adult patients admitted with community-acquired pneumonia: a one year prospective study of 346 consecutive patients. Thorax 1996; 51(2): 179–84PubMedCrossRef

117.

Norrby SR, Petermann W, Willcox PA, et al. A comparative study of levofloxacin and ceftriaxone in the treatment of hospitalized patients with pneumonia. Scand J Infect Dis 1998; 30(4): 397–404PubMedCrossRef

118.

Dansey RD, Jacka PJ, Strachan SA, et al. Comparison of cefotaxime with ceftriaxone given intramuscularly 12-hourly for community-acquired pneumonia. Diagn Microbiol Infect Dis 1992; 15(1): 81–4PubMedCrossRef

119.

Van den Brande P, Vondra V, Vogel F, et al. Sequential therapy with cefuroxime followed by cefuroxime axetil in community-acquired pneumonia. Chest 1997; 112(2): 406–15PubMedCrossRef

120.

Mills GD, Oehley MR, Arrol B. Effectiveness of beta lactam antibiotics compared with antibiotics active against atypical pathogens in non-severe community acquired pneumonia: meta-analysis. BMJ 2005; 330(7489): 456PubMedCrossRef

121.

Shefet D, Robenshtok E, Paul M, et al. Empirical atypical coverage for inpatients with community-acquired pneumonia: systematic review of randomized controlled trials. Arch Intern Med 2005; 165(17): 1992–2000PubMedCrossRef

122.

Finch R, Schurmann D, Collins O, et al. Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral coamoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment. Antimicrob Agents Chemother 2002; 46(6): 1746–54PubMedCrossRef

123.

Correa JC, Badaro R, Bumroongkit C, et al. Randomized, open-label, parallel-group, multicenter study of the efficacy and tolerability of IV gatifloxacin with the option for oral stepdown gatifloxacin versus IV ceftriaxone (with or without erythromycin or clarithromycin) with the option for oral stepdown clarithromycin for treatment of patients with mild to moderate community-acquired pneumonia requiring hospitalization. Clin Ther 2003; 25(5): 1453–68PubMedCrossRef

124.

Frank E, Liu J, Kinasewitz G, et al. A multicenter, open-label, randomized comparison of levofloxacin and azithromycin plus ceftriaxone in hospitalized adults with moderate to severe community-acquired pneumonia. Clin Ther 2002; 24(8): 1292–308PubMedCrossRef

125.

Vardakas KZ, Siempos II, Grammatikos A, et al. Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trials. CMAJ 2008; 179(12): 1269–77PubMedCrossRef

126.

Bjerre LM, Verheij TJ, Kochen MM. Antibiotics for community acquired pneumonia in adult outpatients. Cochrane Database Syst Rev 2009; (4): CD002109

127.

Dalhoff A. Immunomodulatory activities of fluoroquinolones. Infection 2005; 33Suppl. 2: 55–70PubMedCrossRef

128.

Tamaoki J, Kadota J, Takizawa H. Clinical implications of the immunomodulatory effects of macrolides. Am J Med 2004; 117Suppl. 9A: 5–11S

129.

de la Campa AG, Ardanuy C, Balsalobre L, et al. Changes in fluoroquinolone-resistant Streptococcus pneumoniae after 7-valent conjugate vaccination, Spain. Emerg Infect Dis 2009; 15(6): 905–11PubMedCrossRef

130.

Blasi F, Cazzola M, Tarsia P, et al. Azithromycin and lower respiratory tract infections. Expert Opin Pharmacother 2005; 6(13): 2335–51PubMedCrossRef

131.

Calbo E, Alsina M, Rodriguez-Carballeira M, et al. Systemic expression of cytokine production in patients with severe pneumococcal pneumonia: effects of treatment with a beta-lactam versus a fluoroquinolone. Antimicrob Agents Chemother 2008; 52(7): 2395–402PubMedCrossRef

132.

Li JZ, Winston LG, Moore DH, et al. Efficacy of short-course antibiotic regimens for community-acquired pneumonia: a meta-analysis. Am J Med 2007; 120(9): 783–90PubMedCrossRef

133.

Contopoulos-Ioannidis DG, Ioannidis JP, Chew P, et al. Meta-analysis of randomized controlled trials on the comparative efficacy and safety of azithromycin against other antibiotics for lower respiratory tract infections. J Antimicrob Chemother 2001; 48(5): 691–703PubMedCrossRef

134.

Foulds G, Shepard RM, Johnson RB. The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother 1990; 25Suppl. A: 73–82PubMedCrossRef

135.

Christ-Crain M, Stolz D, Bingisser R, et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 2006; 174(1): 84–93PubMedCrossRef

136.

van der Eerden MM, Vlaspolder F, de Graaff CS, et al. Comparison between pathogen directed antibiotic treatment and empirical broad spectrum antibiotic treatment in patients with community acquired pneumonia: a prospective randomised study. Thorax 2005; 60(8): 672–8PubMedCrossRef

137.

Leroy O, Saux P, Bedos JP, et al. Comparison of levofloxacin and cefotaxime combined with ofloxacin for ICU patients with community-acquired pneumonia who do not require vasopressors. Chest 2005; 128(1): 172–83PubMedCrossRef

138.

Geddes A, Thaler M, Schonwald S, et al. Levofloxacin in the empirical treatment of patients with suspected bacteraemia/sepsis: comparison with imipenem/cilastatin in an open, randomized trial. J Antimicrob Chemother 1999; 44(6): 799–810PubMedCrossRef

139.

Fink MP, Snydman DR, Niederman MS, et al. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group. Antimicrob Agents Chemother 1994; 38(3): 547–57PubMedCrossRef

140.

Marrie TJ, Lau CY, Wheeler SL, et al. A controlled trial of a critical pathway for treatment of community-acquired pneumonia: CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin. JAMA 2000; 283(6): 749–55PubMedCrossRef

141.

Martinez JA, Horcajada JP, Almela M, et al. Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2003; 36(4): 389–95PubMedCrossRef

142.

Waterer GW, Somes GW, Wunderink RG. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 2001; 161(15): 1837–42PubMedCrossRef

143.

Mufson MA, Stanek RJ. Bacteremic pneumococcal pneumonia in one American City: a 20-year longitudinal study, 1978–1997. Am J Med 1999; 107(1A): 34S–43SPubMedCrossRef

144.

Safdar N, Handelsman J, Maki DG. Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis. Lancet Infect Dis 2004; 4(8): 519–27PubMedCrossRef

145.

El-Solh AA, Sikka P, Ramadan F, et al. Etiology of severe pneumonia in the very elderly. Am J Respir Crit Care Med 2001; 163(3): 645–51PubMed

146.

Chapman TM, Perry CM. Cefepime: a review of its use in the management of hospitalized patients with pneumonia. Am J Respir Med 2003; 2(1): 75–107PubMedCrossRef

147.

Paul M, Benuri-Silbiger I, Soares-Weiser K, et al. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. BMJ 2004; 328(7441): 668PubMedCrossRef

148.

Chastre J, Wolff M, Fagon JY, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 2003; 290(19): 2588–98PubMedCrossRef

149.

Bruns AH, Oosterheert JJ, Hustinx WN, et al. Time for first antibiotic dose is not predictive for the early clinical failure of moderate-severe community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 2009; 28(8): 913–9PubMedCrossRef

150.

Pines JM. Time to first antibiotic dose measurement in community-acquired pneumonia: time for a change [letter]. Ann Emerg Med 2009; 54(2): 312PubMedCrossRef

151.

Wachter RM, Flanders SA, Fee C, et al. Public reporting of antibiotic timing in patients with pneumonia: lessons from a flawed performance measure. Ann Intern Med 2008; 149(1): 29–32PubMed

152.

Shah D, Dang MD, Hasbun R, et al. Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistance. Expert Rev Anti Infect Ther 2010; 8(5): 555–64PubMedCrossRef

153.

Simor AE. Diagnosis, management, and prevention of Clostridium difficile infection in long-term care facilities: a review. J Am Geriatr Soc 2010; 58(8): 1556–64PubMedCrossRef

154.

Heinlen L, Ballard JD. Clostridium difficile infection. Am J Med Sci 2010; 340(3): 247–52PubMedCrossRef

155.

Wenger NS, Roth CP, Shekelle P. Introduction to the assessing care of vulnerable elders-3 quality indicator measurement set. J Am Geriatr Soc 2007; 55Suppl. 2: S247–52PubMedCrossRef

156.

Arora VM, Johnson M, Olson J, et al. Using assessing care of vulnerable elders quality indicators to measure quality of hospital care for vulnerable elders. J Am Geriatr Soc 2007; 55(11): 1705–11PubMedCrossRef

157.

Cortoos PJ, Simoens S, Peetermans W, et al. Implementing a hospital guideline on pneumonia: a semi-quantitative review. Int J Qual Health Care 2007; 19(6): 358–67PubMedCrossRef

158.

Barlow GD, Lamping DL, Davey PG, et al. Evaluation of outcomes in community-acquired pneumonia: a guide for patients, physicians, and policy-makers. Lancet Infect Dis 2003; 3(8): 476–88PubMedCrossRef

159.

Metersky ML. Community-acquired pneumonia: process of care studies. Curr Opin Infect Dis 2002; 15(2): 169–74PubMedCrossRef

160.

Fiel S. Guidelines and critical pathways for severe hospital-acquired pneumonia. Chest 2001; 119(2 Suppl.): 412–8SCrossRef

Titel: Elderly Patients with Community-Acquired Pneumonia
Optimal Treatment Strategies
verfasst von: Dr Ulrich Thiem
Hans-Jürgen Heppner
Ludger Pientka
Publikationsdatum: 01.07.2011
Verlag: Springer International Publishing
Erschienen in: Drugs & Aging / Ausgabe 7/2011
Print ISSN: 1170-229X
Elektronische ISSN: 1179-1969
DOI: https://doi.org/10.2165/11591980-000000000-00000

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2011

Co-Morbidity and Potential Treatment Conflicts in Elderly Heart Failure Patients

Ketorolac 0.45% Ophthalmic Solution

Variation Over Time in the Association between Polypharmacy and Mortality in the Older Population

Polypharmacy in the Elderly

Clinical, Demographic and Functional Characteristics Associated with Pharmacotherapy for Heart Failure in Older Home Care Clients

Combination Therapy for Alzheimer’s Disease